Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Crystallins are a major class of water-soluble structural proteins that constitute the majority of the vertebrate eye lens and cornea, where they are essential for maintaining transparency and a high refractive index [13, 15]. They are categorized into three main families: alpha, beta, and gamma crystallins. Alpha-crystallins, comprising alpha-A (CRYAA) and alpha-B (CRYAB) subunits, belong to the small heat shock protein (sHSP) family and function as molecular chaperones that prevent the non-specific aggregation of misfolded proteins [1, 11]. Beta and gamma crystallins primarily serve structural roles but also participate in calcium signaling and UV protection [11, 13]. The misfolding and subsequent aggregation of these proteins into insoluble amyloids is the primary cause of cataracts, the leading cause of blindness globally [3, 10]. Beyond the ocular lens, alpha-B crystallin is widely expressed in tissues such as the heart, brain, and skeletal muscle, where it plays roles in neuroprotection, muscle contraction, and the inhibition of apoptosis [6, 12]. In cancer, alpha-B crystallin is often overexpressed and acts as a 'malignant chaperone,' promoting tumor cell survival and resistance to chemotherapy by inhibiting pro-apoptotic pathways [6]. Therapeutic development focuses on pharmacological chaperones, such as lanosterol and oxysterol derivatives (e.g., VP1-001), which aim to stabilize the native protein structure and reverse aggregation in cataracts [8, 9]. Additionally, mini-chaperone peptides derived from alpha-crystallin are being explored for their potential to treat neurodegenerative and inflammatory diseases [7, 14].
Pharmacological chaperone that binds to and stabilizes the native or soluble forms of crystallin proteins, preventing or reversing their aggregation into insoluble amyloids [3, 8]. It also acts as a chaperone mimetic to inhibit apoptosis and protect cells from oxidative stress [1, 6].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Crystallin (CRY).